IL201392A - Use of Compounds 4 - (Pyrrolidine - 1 - Eil) Quinoline for Preparing Medicines to Kill Clinically Dormant Microorganisms - Google Patents
Use of Compounds 4 - (Pyrrolidine - 1 - Eil) Quinoline for Preparing Medicines to Kill Clinically Dormant MicroorganismsInfo
- Publication number
- IL201392A IL201392A IL201392A IL20139209A IL201392A IL 201392 A IL201392 A IL 201392A IL 201392 A IL201392 A IL 201392A IL 20139209 A IL20139209 A IL 20139209A IL 201392 A IL201392 A IL 201392A
- Authority
- IL
- Israel
- Prior art keywords
- pyrrolidin
- medicaments
- production
- quinoline compounds
- clinically latent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D345/00—Heterocyclic compounds containing rings having selenium or tellurium atoms as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0709489A GB0709489D0 (en) | 2007-05-17 | 2007-05-17 | New use |
| GB0807591A GB0807591D0 (en) | 2008-04-25 | 2008-04-25 | New use |
| PCT/GB2008/001694 WO2008142384A1 (en) | 2007-05-17 | 2008-05-16 | Use of 4-(pyrrolidin-1-yl)quinoline compounds to kill clinically latent microorganisms |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL201392A0 IL201392A0 (en) | 2010-05-31 |
| IL201392A true IL201392A (en) | 2016-03-31 |
Family
ID=39672613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL201392A IL201392A (en) | 2007-05-17 | 2009-10-11 | Use of Compounds 4 - (Pyrrolidine - 1 - Eil) Quinoline for Preparing Medicines to Kill Clinically Dormant Microorganisms |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8759348B2 (enExample) |
| EP (1) | EP2182950B8 (enExample) |
| JP (1) | JP5474768B2 (enExample) |
| KR (1) | KR101599384B1 (enExample) |
| CN (1) | CN101795688B (enExample) |
| AU (1) | AU2008252636B2 (enExample) |
| BR (1) | BRPI0811745B1 (enExample) |
| CA (1) | CA2684692C (enExample) |
| DK (1) | DK2182950T3 (enExample) |
| ES (1) | ES2637999T3 (enExample) |
| HR (1) | HRP20171553T1 (enExample) |
| HU (1) | HUE034298T2 (enExample) |
| IL (1) | IL201392A (enExample) |
| MX (1) | MX2009012390A (enExample) |
| NZ (1) | NZ580625A (enExample) |
| PL (1) | PL2182950T3 (enExample) |
| PT (1) | PT2182950T (enExample) |
| RU (1) | RU2520766C2 (enExample) |
| SI (1) | SI2182950T1 (enExample) |
| WO (1) | WO2008142384A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010095522A (ja) * | 2008-09-19 | 2010-04-30 | Sumitomo Chemical Co Ltd | 植物病原菌による植物病害を防除又は予防するための農業用組成物 |
| SI2552440T1 (sl) | 2010-03-30 | 2019-03-29 | Helperby Therapeutics Limited | Nove kombinacije in uporaba |
| EP2569302A1 (en) * | 2010-05-13 | 2013-03-20 | Amgen, Inc | Heteroaryloxyheterocyclyl compounds as pde10 inhibitors |
| GB201013207D0 (en) | 2010-08-05 | 2010-09-22 | Helperby Therapeutics Ltd | Novel combination |
| WO2012017215A1 (en) | 2010-08-05 | 2012-02-09 | Helperby Therapeutics Limited | Combination of a pyrroloquinoline compound and a beta-lactam antimicrobial agent, mupirocin or chlorhexidine |
| GB201015079D0 (en) | 2010-09-10 | 2010-10-27 | Helperby Therapeutics Ltd | Novel use |
| JP6804096B2 (ja) | 2015-04-11 | 2020-12-23 | ヘルパービー セラピューティクス リミテッドＨｅｌｐｅｒｂｙ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ | 口腔用組成物 |
| US10329257B2 (en) | 2015-08-13 | 2019-06-25 | The Broad Institute, Inc. | Compositions and methods for treating tuberculosis |
| GB201518969D0 (en) | 2015-10-27 | 2015-12-09 | Helperby Therapeutics Ltd | Triple combination |
| US11253511B2 (en) | 2016-01-04 | 2022-02-22 | The Johns Hopkins University | Use of low dose emetine for inhibition of human cytomegalovirus (HCMV) |
| KR102665309B1 (ko) * | 2016-10-27 | 2024-05-10 | 주식회사 엘지생활건강 | 코디세핀을 포함하는 구강질환 예방 또는 치료용 조성물 |
| GB201703898D0 (en) | 2017-03-10 | 2017-04-26 | Helperby Therapeautics Ltd | Method |
| RU2664177C1 (ru) * | 2017-08-07 | 2018-08-15 | федеральное государственное бюджетное образовательное учреждение высшего образования "Омский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО ОмГМУ Минздрава России) | Способ лечения абсцедирующих фурункулов верхней и нижней зон лица |
| CN111163766A (zh) * | 2017-08-17 | 2020-05-15 | 医肯纳肿瘤学公司 | Ahr抑制剂和其用途 |
| US10668046B2 (en) | 2017-12-18 | 2020-06-02 | Ansella Therapeutics, Inc. | Compositions and methods for preventing and treating conditions |
| CN110897032B (zh) * | 2019-11-19 | 2025-10-14 | 华南理工大学 | 一种发酵饲料蛋白及其制备方法与应用 |
| RU2758056C2 (ru) * | 2019-11-21 | 2021-10-26 | федеральное государственное бюджетное образовательное учреждение высшего образования "Ставропольский государственный аграрный университет" | Препарат для лечения отитов бактериальной и грибковой этиологии у собак |
| CN111544599B (zh) * | 2020-07-10 | 2020-12-01 | 有术肌肤管理(深圳)有限公司 | 一种用于治疗痤疮的化合物及其用于制备药物或化妆品的用途 |
| KR102461715B1 (ko) * | 2020-10-12 | 2022-11-02 | 대한민국 | 항균 및 항진균 활성을 나타내는 신균주 페니실리움 비세티 및 이의 용도 |
| CN114831924A (zh) * | 2021-03-17 | 2022-08-02 | 武汉恒信源药业有限公司 | 一种乌洛托品及其化合物的阴道局部给药制剂及用途 |
| CN113528388A (zh) * | 2021-07-19 | 2021-10-22 | 海南大学 | 珊瑚共生链霉菌、发酵生产放线菌素d的方法及应用 |
| SMT202500447T1 (it) | 2021-11-02 | 2026-01-12 | Flare Therapeutics Inc | Agonisti inversi di pparg e loro usi |
| JP2025513455A (ja) | 2022-04-22 | 2025-04-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | 疼痛の治療のためのヘテロアリール化合物 |
| CN117323339A (zh) * | 2023-09-05 | 2024-01-02 | 中国科学院广州生物医药与健康研究院 | 偶氮丝氨酸在制备抗分枝杆菌的药物中的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW477787B (en) * | 1996-08-27 | 2002-03-01 | Pfizer | Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same |
| EP2048142A3 (en) * | 2001-04-26 | 2009-04-22 | Eisai R&D Management Co., Ltd. | Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof |
| AU2002338896B2 (en) * | 2001-05-21 | 2006-04-27 | F.Hoffman-La Roche Ag | Quinoline derivatives as ligands for the neuropeptide Y receptor |
| US6787558B2 (en) * | 2001-09-28 | 2004-09-07 | Hoffmann-La Roche Inc. | Quinoline derivatives |
| EP1451156A4 (en) * | 2001-11-27 | 2005-05-25 | Merck & Co Inc | 4-AMINOCHINOLINVERBINDUNGEN |
| PL372295A1 (en) * | 2002-02-04 | 2005-07-11 | F.Hoffmann-La Roche Ag | Quinoline derivatives as npy antagonists |
| CA2489560A1 (en) * | 2002-06-27 | 2004-01-08 | Schering Aktiengesellschaft | Substituted quinoline ccr5 receptor antagonists |
| WO2004016321A2 (en) * | 2002-08-19 | 2004-02-26 | Avi Elbaz | Proprioceptive/kinesthetic apparatus and method |
| JP4602903B2 (ja) * | 2002-10-10 | 2010-12-22 | モルフォケム アクチェンゲゼルシャフト フュア コンビナトリシェ ヘミー | 抗菌活性を有する新規化合物 |
| CL2004000409A1 (es) * | 2003-03-03 | 2005-01-07 | Vertex Pharma | Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu |
| DE102004041163A1 (de) * | 2004-08-25 | 2006-03-02 | Morphochem Aktiengesellschaft für kombinatorische Chemie | Neue Verbindungen mit antibakterieller Aktivität |
| WO2006071875A1 (en) | 2004-12-29 | 2006-07-06 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
| US20060183763A1 (en) * | 2004-12-31 | 2006-08-17 | Pfizer Inc | Novel pyrrolidyl derivatives of heteroaromatic compounds |
| GB0522715D0 (en) * | 2005-11-08 | 2005-12-14 | Helperby Therapeutics Ltd | New use |
-
2008
- 2008-05-16 US US12/600,470 patent/US8759348B2/en not_active Expired - Fee Related
- 2008-05-16 NZ NZ580625A patent/NZ580625A/en not_active IP Right Cessation
- 2008-05-16 CN CN200880016456.XA patent/CN101795688B/zh not_active Expired - Fee Related
- 2008-05-16 DK DK08750626.7T patent/DK2182950T3/da active
- 2008-05-16 PT PT87506267T patent/PT2182950T/pt unknown
- 2008-05-16 EP EP08750626.7A patent/EP2182950B8/en not_active Not-in-force
- 2008-05-16 WO PCT/GB2008/001694 patent/WO2008142384A1/en not_active Ceased
- 2008-05-16 JP JP2010507981A patent/JP5474768B2/ja not_active Expired - Fee Related
- 2008-05-16 CA CA2684692A patent/CA2684692C/en not_active Expired - Fee Related
- 2008-05-16 ES ES08750626.7T patent/ES2637999T3/es active Active
- 2008-05-16 KR KR1020097026394A patent/KR101599384B1/ko not_active Expired - Fee Related
- 2008-05-16 MX MX2009012390A patent/MX2009012390A/es active IP Right Grant
- 2008-05-16 AU AU2008252636A patent/AU2008252636B2/en not_active Ceased
- 2008-05-16 RU RU2009146828/15A patent/RU2520766C2/ru not_active IP Right Cessation
- 2008-05-16 HU HUE08750626A patent/HUE034298T2/en unknown
- 2008-05-16 HR HRP20171553TT patent/HRP20171553T1/hr unknown
- 2008-05-16 BR BRPI0811745-4A patent/BRPI0811745B1/pt not_active IP Right Cessation
- 2008-05-16 PL PL08750626T patent/PL2182950T3/pl unknown
- 2008-05-16 SI SI200831883T patent/SI2182950T1/en unknown
-
2009
- 2009-10-11 IL IL201392A patent/IL201392A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| AU2008252636A1 (en) | 2008-11-27 |
| SI2182950T1 (en) | 2018-01-31 |
| HRP20171553T1 (hr) | 2017-12-15 |
| KR20100021476A (ko) | 2010-02-24 |
| NZ580625A (en) | 2011-12-22 |
| IL201392A0 (en) | 2010-05-31 |
| EP2182950B8 (en) | 2017-08-23 |
| KR101599384B1 (ko) | 2016-03-03 |
| HUE034298T2 (en) | 2018-02-28 |
| BRPI0811745B1 (pt) | 2019-06-04 |
| DK2182950T3 (da) | 2017-11-06 |
| CN101795688A (zh) | 2010-08-04 |
| WO2008142384A1 (en) | 2008-11-27 |
| US20100305065A1 (en) | 2010-12-02 |
| BRPI0811745A2 (pt) | 2014-11-11 |
| EP2182950A1 (en) | 2010-05-12 |
| PL2182950T3 (pl) | 2018-01-31 |
| JP2010527346A (ja) | 2010-08-12 |
| RU2520766C2 (ru) | 2014-06-27 |
| AU2008252636B2 (en) | 2013-10-31 |
| PT2182950T (pt) | 2017-09-11 |
| RU2009146828A (ru) | 2011-06-27 |
| CN101795688B (zh) | 2015-05-20 |
| CA2684692A1 (en) | 2008-11-27 |
| JP5474768B2 (ja) | 2014-04-16 |
| CA2684692C (en) | 2016-07-05 |
| US8759348B2 (en) | 2014-06-24 |
| ES2637999T3 (es) | 2017-10-18 |
| MX2009012390A (es) | 2010-06-23 |
| EP2182950B1 (en) | 2017-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL201392A0 (en) | Use of 4 - pyrrolidin- 1 - yl) quinoline compounds to kill clinically latent microorganisms | |
| EP2209900B8 (en) | Use of bacteria for the production of bioenergy | |
| IL205671A0 (en) | Novel cyclic hydrocarbon compounds for the treatment of diseases | |
| ZA201001304B (en) | Compositions for the treatment of neoplastic diseases | |
| EP2225002A4 (en) | RNA INTERFERENCE FOR THE TREATMENT OF CARDIAC SUFFICIENCIES | |
| ZA200808178B (en) | Imidazolothiazole compounds for the treatment of disease | |
| EP2155197A4 (en) | TREATMENT OF LYSOSOMAL STORAGE DISEASES | |
| ZA200905012B (en) | Process for the preparation of certain substituted sulfimines | |
| GB0908173D0 (en) | Process for facilitating the management of care | |
| ZA200903533B (en) | Process for the preparation of rosuvastatin | |
| IL203051A (en) | Use of alpha-ketoglutarate for drug preparation | |
| IL187904A (en) | Use of quinoline derivatives for the preparation of bacterial preparations for the treatment of bacteria caused by bacteria | |
| ZA200907811B (en) | Process for the manufacture of p4o6 | |
| ZA201108057B (en) | 6'-sialyllactose salta and process for their synthesis and for the synthesis of other a-sialyloligosaccharides | |
| IL212057A0 (en) | Compositions for the treatment of bowel diseases with granulated mesalamine | |
| SI1844036T1 (sl) | Postopek za pripravo aripiprazola | |
| GB0604780D0 (en) | Use of substituted piperazine compounds for the treatment of food related disorders | |
| GB201019043D0 (en) | Use of 2',5'-oligoadenylate derivative compounds | |
| AU2007907021A0 (en) | Antibodies for the treatment of periodontal disease | |
| HK1139045A (en) | Use of ranolazine for the treatment of non-coronary microvascular diseases | |
| GB201009094D0 (en) | Compounds for the treatment of closridium difficile-associated disease | |
| AU2010901601A0 (en) | Compound for the treatment of respiratory condition or disease | |
| HK1129680A (en) | Compounds for the treatment of periodontal disease | |
| HK1144778A (en) | Compounds for the treatment of metabolic disorders | |
| AU2006902494A0 (en) | Breast health formula |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |